MEN2: RET gene, sequencing analysis-994
Test info
This test can be used to identify genetic variations in the RET gene that are causative for MEN2.
Specimen
Submission of the minimum volume does not allow for repeat testing
Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting
Lavender (EDTA), 4mL
Yellow ACD (A or B)
Yellow ACD (A or B)
Ambient (preferred) - 28 days
Refrigerated - 28 days
- Hemolysis
- Frozen specimen
Performance
Polymerase Chain Reaction (PCR) of targeted RET gene exons, DNA sequencing of those PCR products
Clinical and Interpretive info
An interpretive report will be provided
Germline mutations in the RET gene on chromosome 10 are causative for multiple endocrine neoplasia, type 2 (MEN2), a monogenic, autosomal-dominant hereditary cancer syndrome. The vast majority (>95%) of MEN2 cases have RET gene mutations in exons 10, 11, 13, 14, 15, or 16. MEN2 is characterized by the development of medullary thyroid carcinoma (MTC) and sometimes includes pheochromocytoma (PHEO) and hyperparathyroidism (HPT).
Billing
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.
- Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
- All information requested is required in order for your request to be completed